Genetic testing by Invitae 330 Next-Generation Sequencing Inherited Retinal Disease panel (Spark Therapeutic Initiative, San Francisco, CA, USA) revealed that both parents did not have the PAX2 mutation (C > G p. (Tyr73*) at position 219 in exon 3) (Figure 3). Here, PAX2 is linked to Abnormal retinal morphology.